Display options
Cite
Adrian T, Sørensen IMH, Knop FK, et al. Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study. Nephrol Dial Transplant. 2021;doi: 10.1093/ndt/gfab266.
Adrian, T., Sørensen, I. M. H., Knop, F. K., Bro, S., Ballegaard, E. L. F., Nordestgaard, B. G., Fuchs, A., Kofoed, K. F., Kühl, J. T., Sigvardsen, P. E., Hornum, M., & Feldt-Rasmussen, B. (2021). Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, . https://doi.org/10.1093/ndt/gfab266
Adrian, Therese, et al. "Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association vol. (2021). doi: https://doi.org/10.1093/ndt/gfab266
Adrian T, Sørensen IMH, Knop FK, Bro S, Ballegaard ELF, Nordestgaard BG, Fuchs A, Kofoed KF, Kühl JT, Sigvardsen PE, Hornum M, Feldt-Rasmussen B. Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study. Nephrol Dial Transplant. 2021 Sep 10; doi: 10.1093/ndt/gfab266. Epub 2021 Sep 10. PMID: 34505899.
Copy Download .nbib Format: NLM
Share it on

Nephrol Dial Transplant. 2021 Sep 10; doi: 10.1093/ndt/gfab266. Epub 2021 Sep 10.

Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Therese Adrian, Ida M H Sørensen, Filip K Knop, Susanne Bro, Ellen L F Ballegaard, Børge G Nordestgaard, Andreas Fuchs, Klaus F Kofoed, Jørgen T Kühl, Per E Sigvardsen, Mads Hornum, Bo Feldt-Rasmussen

Affiliations

  1. Department of Nephrology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  2. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
  3. Center for Clinical Metabolic Research, Copenhagen University Hospital-Gentofte Hospital, Hellerup, Denmark.
  4. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  5. Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  6. Department of Clinical Biochemistry, and the Copenhagen General Population Study, Copenhagen University Hospital-Herlev and Gentofte Hospital, Herlev, Denmark.
  7. The Copenhagen City Heart Study, Copenhagen University Hospital-Frederiksberg Hospital, Frederiksberg, Denmark.
  8. Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  9. Department of Radiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.

PMID: 34505899 DOI: 10.1093/ndt/gfab266

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and represents a wide spectrum ranging from mild steatosis over non-alcoholic steatohepatitis with and without fibrosis to overt cirrhosis. Patients with NAFLD have a high risk of developing cardiovascular disease and chronic kidney disease (CKD). So far, there is scarce evidence of the prevalence of NAFLD among patients with CKD. We investigated the prevalence of moderate-to-severe hepatic steatosis graded according to the definition of NAFLD in a cohort of patients with CKD.

METHODS: Hepatic liver fat content was evaluated by computed tomography (CT) scan in 291 patients from the Copenhagen Chronic Kidney Disease Cohort Study and in 866 age- and sex-matched individuals with normal kidney function from the Copenhagen General Population Study. Liver attenuation density <48 Hounsfield units was used as cut-off value for moderate-to-severe hepatic steatosis.

RESULTS: The prevalence of moderate-to-severe hepatic steatosis was 7.9% and 10.7% (P = 0.177) among patients with CKD and controls, respectively. No association between liver fat content and CKD stage was found. In the pooled data set from both cohorts, adjusted odds ratios for moderate-to-severe hepatic steatosis among persons with diabetes, overweight and obesity amounted to 3.1 (95% confidence interval (CI) 1.6-5.9), 14.8 (95% CI 4.6-47.9) and 42.0 (95% CI 12.9-136.6), respectively.

CONCLUSIONS: In a cohort of 291 patients with CKD, kidney function was not associated with the prevalence of moderate-to-severe hepatic steatosis as assessed by CT scan.

© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Keywords: chronic kidney disease; computed tomography; diabetes; hepatic steatosis; non-alcoholic fatty liver disease

Publication Types